This publication was downloaded for exclusive use by: aiman.mohamad@macquarie.com

Flashnote 17 May 2019

EQUITIES

SCGB MK Price (at 14:31, 16 May 2019 GMT)		Neutral RM1.94
Valuation - PER	RM	1.77-2.49
12-month target	RM	2.00
Upside/Downside	%	+3.1
12-month TSR	%	+6.7
Volatility Index		Medium
GICS sector	Ca	apital Goods
Market cap	RMm	2,457
Market cap	US\$m	588
Free float	%	26
30-day avg turnover	US\$m	0.5
Number shares on issue	m	1,266

Investment fundamentals

Year end 31 Dec		2018A	2019E	2020E	2021E
Revenue	m	2,256.8	2,383.3	2,598.3	2,229.1
EBITDA	m	214.6	220.4	229.4	226.1
EBIT	m	174.6	174.8	179.0	171.2
Reported profit	m	144.7	142.8	148.8	147.2
Adjusted profit	m	144.7	142.8	148.8	147.2
EPS rep	sen	11.2	11.0	11.5	11.4
EPS rep growth	%	9.3	-1.3	4.2	-1.1
EPS adj	sen	11.2	11.0	11.5	11.4
EPS adj growth	%	9.3	-1.3	4.2	-1.1
PER rep	х	17.3	17.6	16.9	17.0
PER adj	х	17.3	17.6	16.9	17.0
Total DPS	sen	7.0	7.0	7.0	8.0
Total div yield	%	3.6	3.6	3.6	4.1
ROA	%	9.8	10.0	9.7	8.6
ROE	%	25.5	23.1	22.1	20.3
EV/EBITDA	х	9.9	9.7	9.3	9.5
Net debt/equity	%	-62.7	-70.7	-89.2	-117.4
P/BV	х	4.2	3.9	3.6	3.3

SCGB MK rel KLCI performance, & rec history



Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, May 2019 (all figures in MYR unless noted)

Analysts

Macquarie Capital Securities (Malaysia) Sdn. Bhd.



Aiman Mohamad +60 3 2059 8986 aiman.mohamad@macquarie.com Malaysia

Sunway Construction Group (SCGB MK) Results in-line, precast showing signs of improvement

Event

 Sunway Construction (SunCon) reported its 1Q19 results with an adj. PAT of RM32mn (-10% YoY), tracking in-line with MQ and consensus FY19E estimates at 23% and 21%, respectively. 1Q19 revenue registered at RM440mn (-17% YoY), tracking a tad behind MQ and consensus FY19E estimates at 18% and 19%, respectively.

Impact

- Outstanding orderbook stood at RM5.7bn, with YTD order wins of RM1.01bn. SunCon's YTD order wins are already ahead of management's FY19E target of RM1.5bn (MQ target of RM2bn). YTD order wins were mainly supported by the TNB HQ campus worth RM781mn on top of precast orders, piling works and in-house projects to make up for the RM1.01bn of order wins.
- **Construction division**. The division recorded total revenue of RM407mn (-17% YoY) in 1Q19, followed by an EBIT of RM38mn (-4% YoY). Revenue was lower due to the completion of the Parcel F Puturajaya project, which no longer contributes to the Group's revenue. 1Q19 EBIT margin was higher YoY at 9.3% vs 8.0% as higher margin projects have contributed to the revenue mix. Management has guided that it is looking to secure jobs overseas, primarily highway projects in India. At home, SunCon is tendering for the ECRL and Large Scale Solar 3 (LSS3) projects. SunCon is confident to secure the latter project as it is entering into the tender with an experienced foreign partner in solar systems.
- Precast division. The division recorded total revenue of RM33mn (-11% YoY). We previously highlighted the potential drag from the precast division in 1H19 evidently the division only recorded an EBIT of RM0.3mn (-91% YoY) taking the precast EBIT margin down to 1% from 10% recorded in 1Q18. Per management guidance, it expects the division to improve its margins in 2H19 as the precast orders secured in late FY18 came at significantly higher margins. Recall that the division was loss making in 3Q-4Q FY18.

SunCon 1Q19 results summary

Ests.			Ests.	Actual	Consensus forecast
2,383.3	440.0	18%	2,328.1	440.0	19%
174.8	38.2	22%	180.1	38.2	21%
180.8	40.1	22%	190.3	40.1	21%
142.8	32.2	23%	151.0	32.2	21%
	2,383.3 174.8 180.8 142.8	2,383.3 440.0 174.8 38.2 180.8 40.1	2,383.3440.018%174.838.222%180.840.122%142.832.223%	2,383.3440.018%2,328.1174.838.222%180.1180.840.122%190.3142.832.223%151.0	2,383.3440.018%2,328.1440.0174.838.222%180.138.2180.840.122%190.340.1

Source: Bloomberg, Company data, Macquarie Research, May 2019

Action and recommendation

 On one hand we are positive on SunCon's move to try and secure jobs abroad, but on the other, given the payment terms in India – 40% payment during completion and balance 60% in a 15-year annuity payment poses sizeable risks to SunCon's earnings. We could turn more positive on SunCon if it manages to secure orders locally. Neutral rating reiterated.

Recommendat	ion definitio	ons		Volat	ility index	definition	*	Financial definitions
Macquarie – Asia (SA): Outperform – expe Neutral – expecte Underperform – e Macquarie - Aust Outperform – exp Neutral – expecte Underperform – e Note: expected re stock and should I with volatility risk	ected return > d return from xpected return ralia/New Ze ected return > d return from (xpected return turn is reflectiv	10% -10% to +10 1 <-10% aland 10% 0% to 10% 1 <0% ve of a Medi	% wm Volatility	 Price n Very h expect invest specul High - down a be awa Mediut or down Low-r move n Appli Recon Note: 	novements. igh-highe: ed to move stors should ative. stock shou at least 40	st risk – Sto b up or down d be aware th uld be expect 60% in a yea sk could be s should be exp 0–40% in a yea stock should at least 25–3 lid be expect 25% in a yea lect stocks in ns – 12 mon	bected to move up year. be expected to 30% in a year. ed to move up or ar. Asia/Australia/NZ ths s may differ from	All "Adjusted" data items have had the following adjustments made: Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests EPS = adjusted net profit / efpowa* ROA = adjusted net profit / efpowa* ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit / average total assets ROE = adjusted net profit / average shareholders fund Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).
Recommendat	ion proport	ions – For	quarter en	ding 31 Ma	rch 2019			
Outperform Neutral Underperform	AU/NZ 48.45% 35.27% 16.28%	Asia 56.50% 30.15% 13.35%	RSA 47.06% 32.94% 20.00%	USA 51.94% 42.78% 5.28%	CA 68.53% 24.48% 6.99%	EUR 51.76% 38.19% 10.05%	(for global coverage by I	Macquarie, 3.69% of stocks followed are investment banking clients Macquarie, 2.76% of stocks followed are investment banking clients Macquarie, 0.89% of stocks followed are investment banking clients

Note: This table does not reflect the announced cessation of research services effective April 29, 2019, through our affiliate Macquarie Capital Markets Canada Ltd.

SCGB MK vs KLCI, & rec history



(all figures in MYR currency unless noted)

Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, May 2019

12-month target price methodology

SCGB MK: RM2.00 based on a PER methodology

Company-specific disclosures:

SCGB MK: Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures.

Date	Stock Code (BBG code)	Recommendation	Target Price
14-May-2019	SCGB MK	Neutral	RM2.00
11-Jan-2019	SCGB MK	Neutral	RM1.40
20-Jul-2018	SCGB MK	Neutral	RM2.00
19-Apr-2018	SCGB MK	Outperform	RM2.60
06-Oct-2017	SCGB MK	Outperform	RM2.80
26-Apr-2017	SCGB MK	Outperform	RM2.50
03-Sep-2016	SCGB MK	Outperform	RM1.90

Target price risk disclosures:

SCGB MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital (Ireland) DAC; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Mazi Macquarie Securities (RF) (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn

Macquarie Research

Sunway Construction Group (SCGB MK)

Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

Country-specific disclaimers:

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Ireland) DAC, which is authorised and regulated by the Central Bank of Ireland (No. C186531). France: In France, research is issued and distributed by Macquarie Capital (Ireland) DAC, which is authorised and regulated by the Central Bank of Ireland (No. C186531). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. Thailand. In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId= MDIS03002001000000&serviceId=SDIS03002001000. South Africa: In South Africa, research is issued and distributed by Mazi Macquarie Securities (RF) (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Mazi Macquarie Securities (RF) (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the

content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group

Equities

Asia Research

Head of Equity Research

Jake Lynch (Asia – Head) (852) 3922 3583 Hiroyuki Sakaida (Japan - Head) (813) 3512 6695 Conrad Werner (ASEAN - Head) (65) 6601 0182

Automobiles, Auto Parts

Janet Lewis (China, Japan) (813) 3512 7856 Allen Yuan (China) (8621) 2412 9009 James Hong (Korea) (822) 3705 8661 Amit Mishra (India) (9122) 6720 4084 Robert Pranata (Indonesia) (6221) 2598 8366

(852) 3922 3567

(8862) 2734 7530

(813) 3512 7476 (822) 3705 8676

(9122) 6720 4078

(6221) 2598 8310

(603) 2059 8833

(632) 857 0892

(662) 694 7753

(852) 3922 1291

(632) 857 0892

(65) 6601 0182

(852) 3922 4068

(852) 3922 3581

(852) 3922 3768

(852) 3922 5750

(813) 3512 7879

(822) 3705 4953

(9122) 6720 4085

(6221) 2598 8366

(6221) 2598 8369

(603) 2059 8845

(632) 857 0899

(662) 694 7993

(1 212) 231 6121

(65) 6601 0211

(852) 3922 2019

(44 20) 3037 4873

(44 20) 3037 4893

(9122) 6720 4101

(6221) 2598 8303

(41 22) 818 7712 (813) 3512 7919

(813) 3512 7823

(65) 6601 0182

Banks and Financials

Scott Russell (Asia) Dexter Hsu (China, Taiwan) Keisuke Moriyama (Japan) Jeff Kim (Korea) Suresh Ganapathy (India) Conrad Werner (Singapore) Jayden Vantarakis (Indonesia) Anand Pathmakanthan (Malaysia) Gilbert Lopez (Philippines) Peach Patharavanakul (Thailand)

Basic Materials, Commodities

David Ching (China, Hong Kong)	(852) 3922 1823
Harunobu Goroh (Japan)	(813) 3512 7886
Yasuhiro Nakada (Japan)	(813) 3512 7862
Anna Park (Korea)	(822) 3705 8669
Sumangal Nevatia (India)	(9122) 6720 4093
Jayden Vantarakis (Indonesia)	(6221) 2598 8310

Conglomerates

David Ng (China, Hong Kong) Gilbert Lopez (Philippines) Conrad Werner (Singapore)

Consumer, Gaming

Linda Huang (Asia) Terence Chang (China, Hong Kong) Sunny Chow (China, Hong Kong) Edward Engel (China, Hong Kong) Leon Rapp (Japan) Kwang Cho (Korea) Amit Sinha (India) Robert Pranata (Indonesia) Richardo Walujo (Indonesia) Denise Soon (Malaysia) Karisa Magpayo (Philippines) Chalinee Congmuang (Thailand)

Emerging Leaders

Emerging Leaders	
Corinne Jian (Asia) Marcus Yang (China) Kwang Cho (Korea) Conrad Werner (ASEAN) Bo Denworalak (Thailand)	(8862) 2734 7522 (8621) 2412 9087 (822) 3705 4953 (65) 6601 0182 (662) 694 7774
Infrastructure, Industrials, 7	Fransportation
Patrick Dai (China) Eric Zong (China, Hong Kong) Kunio Sakaida (Japan) James Hong (Korea) Corinne Jian (Taiwan) Inderjeetsingh Bhatia (India)	(8621) 2412 9082 (852) 3922 4749 (813) 3512 7873 (822) 3705 8661 (8862) 2734 7522 (9122) 6720 4087
Internet, Media and Softwar	e
Wendy Huang (Asia) John Wang (China, Hong Kong) Frank Chen (China, Hong Kong) Ellie Jiang (China, Hong Kong) Andy Kim (Korea) Alankar Garude (India)	(852) 3922 3378 (852) 3922 3578 (852) 3922 1433 (852) 3922 1433 (852) 3922 4110 (822) 3705 8690 (9122) 6720 4134
Oil, Gas and Petrochemical	s
Aditya Suresh (Asia) Anna Park (Asia) Yasuhiro Nakada (Japan) Corinne Jian (Taiwan) Ben Shane Lim (Malaysia) Yupapan Polpornprasert (Thailand)	(852) 3922 1265 (822) 3705 8669 (813) 3512 7862 (8862) 2734 7522 (603) 2059 8868 (662) 694 7729
Pharmaceuticals and Health	ncare
David Ng (China, Hong Kong) Xiang Gao (China, Hong Kong) Corinne Jian (China) Mi Hyun Kim (Korea) Alankar Garude (India) Richardo Walujo (Indonesia)	(852) 3922 1291 (8621) 2412 9006 (8862) 2734 7522 (822) 3705 8689 (9122) 6720 4134 (6221) 259 88 369
Property, REIT	
David Ng (China, Hong Kong) Kelvin Tam (China) Nicholas Ting (Hong Kong) Keisuke Moriyama (Japan) Derrick Heng (Singapore) Abhishek Bhandari (India) Richard Danusaputra (Indonesia)	(852) 3922 1291 (852) 3922 1181 (852) 3922 1181 (852) 3922 1398 (813) 3512 7476 (65) 6601 0436 (9122) 6720 4088 (6221) 2598 8368

Technology

Damian Thong (A Jeffrey Ohlweiler Kaylin Tsai (Grea Patrick Liao (Grea Hiroshi Taguchi (Daniel Kim (Korea Abhishek Bhanda	(813) 3512 7877 (8862) 2734 7512 (8862) 2734 7523 (8862) 2734 7523 (8862) 2734 7515 (813) 3512 7867 (822) 3705 8641 (9122) 6720 4088	
Telecoms		
Nathania Nurhalir	Prem Jearajasingam (ASEAN) Nathania Nurhalim (Indonesia) Kervin Sisayan (Philippines)	
Utilities, Rene	ewables	
Hiroyuki Sakaida Patrick Dai (China Sean Hu (China, Kerry Cheng (Chi Inderjeetsingh Bh Karisa Magpayo (a) Hong Kong) na) atia (India) Philippines)	(813) 3512 6695 (8621) 2412 9082 (852) 3922 3571 (8621) 2412 9025 (9122) 6720 4087 (632) 857 0899
Strategy, Cou	intry	
Viktor Shvets (As David Ng (China, Hiroyuki Sakaida Daniel Kim (Korea Jeffrey Ohlweiler Inderjeetsingh Bh Conrad Werner (/ Jayden Vantaraki Anand Pathmaka Gilbert Lopez (Ph Peach Patharava	Hong Kong) (Japan) a) (Taiwan) atia (India) ASEAN, Singapore) s (Indonesia) nthan (Malaysia) ilippines)	(852) 3922 3883 (852) 3922 1291 (813) 3512 6695 (822) 3705 8641 (8862) 2734 7512 (9122) 6720 4087 (65) 6601 0182 (6221) 2598 8310 (603) 2059 8833 (632) 857 0892 (662) 694 7753
Find our rese Macquarie: Thomson: Reuters: Bloomberg: Factset: CapitallQ Email macresear	arch at www.macquariere www.thomson.con www.knowledge.re MAC GO http://www.factset. www.capitaliq.com ch@macquarie.com	n/financial euters.com .com/home.aspx

Asia Sales

Regional Heads of Sales

Miki Edelman (Global)
Amelia Mehta (Asia)
Alan Chen (Asia)
Christina Lee (US)
Mothlib Miah (UK/Europe)
Sandeep Bhatia (India)
Tim Huang (Indonesia)
Thomas Renz (Geneva)
Leslie Hoy (Japan)
Tomohiro Takahashi (Japan)

Regional Heads of Sales cont'd

Aiman Mohamad (Malavsia)

Kervin Sisavan (Philippines)

Bo Denworalak (Thailand)

DJ Kwak (Korea) Nik Hadi (Malavsia) Gino C Rojas (Philippines) Paul Colaco (San Francisco) Eric Lin (Taiwan) Angus Kent (Thailand)

Sales Trading

Mark Weekes (Asia) Stanley Dunda (Indonesia)

(822) 3705 8608 (603) 2059 8888 (632) 857 0861 (1 415) 762 5003 (8862) 2734 7590 (662) 694 7601

(852) 3922 2084

(6221) 515 1555

(603) 2059 8986

(632) 857 0893

(662) 694 7774

Sales Trading cont'd Suhaida Samsudin (Malaysia)

Michael Santos (Philippines) Chris Reale (New York) Marc Rosa (New York) Justin Morrison (Singapore) Brendan Rake (Thailand) Mike Keen (UK/Europe)

(603) 2059 8888 (632) 857 0813 (1 212) 231 2555 (1 212) 231 2555 (65) 6601 0288 (662) 694 7707 (44 20) 3037 4905